BMY
Bristol-Myers Squibb Company Healthcare - Pharmaceuticals Investor Relations →
Bristol-Myers Squibb Company (BMY) closed at $63.64 as of 2026-09-11, trading 24.0% above its 200-week moving average of $51.34. The stock is currently moving closer to the line, down from 30.2% last week. The 14-week RSI sits at 64, indicating neutral momentum.
Trading volume is running at 0.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.08 ratio) is neutral — neither side is clearly dominating.
Over the past 2784 weeks of data, BMY has crossed below its 200-week moving average 27 times. On average, these episodes lasted 27 weeks. Historically, investors who bought BMY at the start of these episodes saw an average one-year return of +4.1%.
With a market cap of $130.0 billion, BMY is a large-cap stock. The company generates a free cash flow yield of 6.2%, which is healthy. Return on equity stands at 46.6%, indicating strong profitability. The stock trades at 5.8x book value.
Over the past 33.8 years, a hypothetical investment of $100 in BMY would have grown to $1508, compared to $3170 for the S&P 500. BMY has returned 8.4% annualized vs 10.8% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 2.4% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BMY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BMY Crosses Below the Line?
Across 21 historical episodes, buying BMY when it crossed below its 200-week moving average produced an average return of -1.5% after 12 months (median +3.0%), compared to +8.3% for the S&P 500 over the same periods. 52% of those episodes were profitable after one year. After 24 months, the average return was -10.0% vs +14.2% for the index.
Each line shows $100 invested at the moment BMY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices BMY would reach each dislocation threshold.
Dislocation Price Levels
Prices where BMY's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-10-29.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $51.84 | Unusually cheap — analysis point |
| Value | +1σ | $55.29 | Cheap vs. own history |
| Fair Value | +0σ | $59.23 | Historical mean behavior |
| Expensive | -1σ | $63.78 | Expensive vs. own history |
| Deep Expensive | -2σ | $69.08 | Unusually expensive — analysis point |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.60 | $2.04 | +27.7% |
| 2026-04-30 | $1.42 | $1.58 | +11.2% |
| 2026-02-05 | $1.20 | $1.26 | +4.6% |
| 2025-10-30 | $1.52 | $1.63 | +7.5% |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from BMY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
BMY has crossed below its 200-week MA 27 times with an average 1-year return of +4.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 1973 | Jul 1973 | 9 | 11.8% | -16.5% | +23186.1% |
| Aug 1973 | Jan 1975 | 77 | 42.8% | -22.2% | +22187.2% |
| Feb 1978 | Mar 1978 | 3 | 3.4% | +16.7% | +20292.0% |
| Oct 1978 | Oct 1978 | 1 | 2.8% | +9.2% | +19248.8% |
| Jul 1979 | Jul 1979 | 1 | 0.7% | +32.9% | +18081.6% |
| Mar 1980 | Mar 1980 | 3 | 2.3% | +83.2% | +18009.7% |
| Jan 1993 | Jan 1995 | 105 | 17.9% | +2.3% | +1395.6% |
| Jul 2000 | Aug 2000 | 5 | 1.4% | +14.0% | +256.9% |
| Sep 2000 | Sep 2000 | 1 | 0.2% | +16.4% | +245.9% |
| Apr 2001 | Jul 2001 | 13 | 8.5% | -43.3% | +215.9% |
| Sep 2001 | Sep 2001 | 1 | 7.4% | -51.0% | +227.4% |
| Oct 2001 | Nov 2001 | 2 | 4.0% | -50.8% | +213.3% |
| Nov 2001 | Feb 2006 | 220 | 60.4% | -48.9% | +209.1% |
| Aug 2006 | Aug 2006 | 3 | 10.7% | +48.3% | +568.0% |
| Jan 2008 | Dec 2008 | 47 | 22.5% | +3.3% | +453.0% |
| Jan 2009 | Jul 2009 | 29 | 17.9% | +17.4% | +436.5% |
| Oct 2016 | Nov 2016 | 4 | 6.6% | +34.7% | +80.6% |
| Jan 2017 | Feb 2017 | 5 | 12.6% | +29.9% | +81.4% |
| Mar 2017 | Jul 2017 | 18 | 4.1% | +19.5% | +64.2% |
| Apr 2018 | Jul 2018 | 15 | 11.4% | -8.3% | +68.8% |
| Oct 2018 | Oct 2019 | 54 | 21.1% | -7.2% | +48.2% |
| Mar 2020 | Mar 2020 | 2 | 9.7% | +33.7% | +69.0% |
| Jul 2023 | Aug 2023 | 3 | 1.9% | -13.8% | +19.3% |
| Sep 2023 | Nov 2024 | 63 | 32.0% | -16.0% | +20.5% |
| Dec 2024 | Jan 2025 | 6 | 2.9% | -1.4% | +23.8% |
| Feb 2025 | Feb 2025 | 3 | 5.4% | +14.5% | +20.2% |
| Mar 2025 | Dec 2025 | 37 | 19.5% | +13.2% | +22.2% |
| Average | 27 | — | +4.1% | — |
Frequently Asked Questions
Is BMY below its 200-week moving average?
No. Bristol-Myers Squibb Company (BMY) is currently 24.0% above its 200-week moving average of $51.34. It would need to fall to $51.34 to cross below the line.
What is BMY's 200-week moving average price?
Bristol-Myers Squibb Company's 200-week moving average is $51.34 as of 2026-09-11. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BMY drops below its 200-week moving average?
BMY has crossed below its 200-week moving average 27 times in our data. On average, buying at that moment produced a one-year return of +4.1%. These dips have historically been decent entry points. These episodes lasted 27 weeks on average.
Is BMY a good value right now?
Here's what our data says about BMY as of 2026-09-11: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 64. Free cash flow yield is 6.2%. Return on equity is 46.6%. Price-to-book is 5.8x. This is not a buy or sell recommendation — always do your own research.
How does BMY compare to the S&P 500?
Over the past 33.8 years, $100 invested in BMY would have grown to $1508, compared to $3170 for the S&P 500. That's 8.4% annualized vs 10.8% for the index. BMY has underperformed the broader market over this period.
Does BMY pay a dividend?
Yes. Bristol-Myers Squibb Company currently pays a dividend yield of 395.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-09-11